In tumors with sporadic NF1 loss, progression-free survival is significantly lower in NF1-deficient individuals compared to other groups for non-small cell lung cancer and acute myeloid leukemia, making NF1 loss a poor prognostic factor (Giraud et al., 2023). This evidence concerns the gene NF1 and acute myeloid leukemia.